Notably, Onalespib has been found to effectively deplete key HR proteins, like CHK1 and RAD51, impairing HR repair and making patient-derived glioma stem cell lines more susceptible to radiation and TMZ (15). Here, CHEK1 is linked to central nervous system cancer.